Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability.

Identification of Mdm2 and JNK as proteins that target degradation of wt p53 prompted us to examine their effect on mutant p53, which exhibits a prolonged half-life. Of five mutant p53 forms studied for association with the targeting molecules, two no longer bound to Mdm2 and JNK. Three mutant forms, which exhibit high expression levels, showed lower affinity for association with Mdm2 and JNK in concordance with greater affinity to p14(ARF), which is among the stabilizing p53 molecules. Monitoring mutant p53 stability in vitro confirmed that, while certain forms of mutant p53 are no longer affected by either JNK or Mdm2, others are targeted for degradation by JNK/Mdm2, albeit at lower efficiency when compared with wt p53. Expression of wt p53 in tumor cells revealed a short half-life, suggesting that the targeting molecules are functional. Forced expression of mutant p53 in p53 null cells confirmed pattern of association with JNK/Mdm2 and prolonged half-life, as found in the tumor cells. Over-expression of Mdm2 in either tumor (which do express endogenous functional Mdm2) or in p53 null cells decreased the stability of mutant p53 suggesting that, despite its expression, Mdm2/JNK are insufficient (amount/affinity) for targeting mutant p53 degradation. Based on both in vitro and in vivo analyses, we conclude that the prolonged half-life of mutant p53 depends on the nature of the mutation, which either alters association with targeting molecules, ratio between p53 and targeting/stabilizing molecules or targeting efficiency.

[1]  A. Fersht,et al.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Zentgraf,et al.  Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation , 1998, Oncogene.

[3]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[4]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[5]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[6]  V. Adler,et al.  JNK targets p53 ubiquitination and degradation in nonstressed cells. , 1998, Genes & development.

[7]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[9]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[10]  K. Aldape,et al.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[12]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[13]  P. Howley,et al.  The Role of E6AP in the Regulation of p53 Protein Levels in Human Papillomavirus (HPV)-positive and HPV-negative Cells* , 1998, The Journal of Biological Chemistry.

[14]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. C. Hu,et al.  JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases , 1997, Oncogene.

[16]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[17]  D. Lane,et al.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.

[18]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[19]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[20]  L. Bracco,et al.  Proteolysis by calpains: a possible contribution to degradation of p53 , 1997, Molecular and cellular biology.

[21]  P. Branton,et al.  Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells , 1997, Journal of virology.

[22]  M. Pagano,et al.  Mechanism of p53 degradation. , 1997, Biochimica et biophysica acta.

[23]  M. Pincus,et al.  Conformation-dependent phosphorylation of p53. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[25]  M. Kubbutat,et al.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability , 1997, Molecular and cellular biology.

[26]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[27]  A. Fornace,et al.  The two faces of tumor suppressor p53. , 1996, The American journal of pathology.

[28]  T. Crook,et al.  Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. , 1996, Virology.

[29]  W. Deppert,et al.  Cooperation of simian virus 40 large and small T antigens in metabolic stabilization of tumor suppressor p53 during cellular transformation , 1995, Journal of virology.

[30]  D. Haber,et al.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. , 1995, Genes & development.

[31]  D. Meek,et al.  p53 Is Phosphorylated in Vitro and in Vivo by an Ultraviolet Radiation-induced Protein Kinase Characteristic of the c-Jun Kinase, JNK1 (*) , 1995, The Journal of Biological Chemistry.

[32]  M. Oren,et al.  Biochemical properties and biological effects of p53. , 1995, Current opinion in genetics & development.

[33]  L. Donehower,et al.  The tumore suppressor p53 , 1993 .

[34]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[35]  Amy Bernard,et al.  Physical and functional interaction between WT1 and p53 proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[37]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[38]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[39]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[40]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[41]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[42]  C. Anderson,et al.  Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen , 1990, Molecular and cellular biology.

[43]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.